🇭🇰 港交所SBP GROUPDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 10-14 18:20:00时区推断·⟳ 抓取 10-14 18:20:32·⚡ 决策 10-15 02:13:25 +7h52m·12.5 天前
中国生物制药：TQ-A3334与bepirovirsen乙肝数据获选2026 AASLD口头/LBA报告，但仅为会议日程预告、今日无新数据
这是一份数据获选在学术会议报告的提前日程公告：真正的临床读数在2026年11月7-8日，今天没有任何疗效数字、监管状态变化或商业指引；对超大市值的中国生物制药缺乏可交易窗口内的收入/利润增量，bepirovirsen日本获批（8月）与B-Well III期方向均为旧闻。当前无可交易edge，应等11月数据本身再研判。
📄 原文SBP GROUP↗ 原文
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 中国生物制药（01177.HK）
软催化无增量：公告仅通知两款乙肝药物数据将于11月7-8日AASLD报告，今日无疗效/安全性数据、无监管或商业状态迁移；公司为超大市值药企，bepirovirsen日本获批为旧闻，不具备可交易窗口内的收入/利润弹性。真正决策点是11月数据读出本身，届时按实际surprise重新研判，而非提前3周埋伏。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
中国生物制药公告两款乙肝在研药获选AASLD 2026口头/LBA报告，但仅为日程预告、无新数据，关键读数在3周后（11月7-8日）；对千亿市值公司属无金额增量的软催化，今日不构成入场理由，AVOID。
🔎 新鲜度:最早出现 2026-10-14 · 扩散 low · price-in 风险 low ↗
关键理由
- 不适用（AVOID）：公告不包含状态迁移，II期/III期数据尚未读出，无法评估相对预期的surprise与业绩弹性
主要风险
- 11月7-8日实际数据若显著超预期（尤其TQ-A3334 48周功能性治愈率与B-Well持久性）可能成为独立硬催化，届时需重新研判，不可凭本预告提前埋伏
- B-Well III期终期结果可能只是GSK已披露topline的完整化，存在标题正面、细节平淡的见光风险
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
公告所述B-Well III期为终期研究结果（end of study）与12周HBsAg预测模型，III期方向及bepirovirsen日本获批均非新增；本次无新数据削弱做多逻辑
检索:bepirovirsen B-Well Phase 3 topline results GSK 功能性治愈率 已披露 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论；AVOID由事件性质（无新增数据+超大市值软催化）直接决定，不依赖先例
方向:未形成交易结论：事件本身无可交易的状态迁移，无需用先例校准方向或胜率
涨幅量级:不足：真正可对标先例应是11月7-8日数据读出后的同类乙肝临床读出反应，而非获选会议报告日程公告
形态:未评估
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`1177.hk 正大天晴 tq-a3334 慢性乙肝 ii期 48周 aasld | sino biopharmaceutical tq-a3334 tlr7 agonist aasld 2026 late breaking abstract | 中国生物制药 bepirovirsen b-well phase 3 aasld 2026 oral prese`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{
原文全文
展开原文 · 4,653 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take
no responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)
VOLUNTARY ANNOUNCEMENT
LATEST RESEARCH RESULTS ON TQ-A3334 “TLR7 AGONIST” AND
BEPIROVIRSEN “ASO”
TO BE PRESENTED AT 2026 AASLD
The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together
with its subsidiaries, the “Group”) announces that the results from a clinical study of TQ-A3334 (a
TLR7 agonist), a national Category 1 innovative drug independently developed by Chia Tai Tianqing
Pharmaceutical Group Co., Ltd. (“CTTQ”), a subsidiary of the Group, have been selected as a “LateBreaking Abstract” (LBA) at The Liver Meeting 2026 of the American Association for the Study of
Liver Diseases (AASLD) and will be presented in the form of an oral presentation. Bepirovirsen (ASO),
a product resulting from the strategic collaboration between CTTQ and GlaxoSmithKline (GSK), has
been selected for 2 oral presentations and 8 poster presentations (including one poster of distinction).
TQ-A3334 (TLR7 agonist)
An LBA:
Title of Abstract: Efficacy and Safety of an Oral TLR7 Agonist Through 48 Weeks in NAs-Treated
Chronic HBV Infection: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Presenter:
Professor Hong Tang, West China Hospital of Sichuan University
Date and Time:
8 November 2026, 5:30 pm – 5:45 pm (local time)
Venue:
Late Breaking Abstract Parallel Session 2
1
About TQ-A3334:
TQ-A3334 is an oral, selective Toll-like receptor 7 (TLR7) agonist that reshapes the body’s immune
response against HBV by activating innate and adaptive immune pathways and inducing interferon and
cytokine responses. It complements the direct antiviral effects of nucleos(t)ide analogues and represents
a significant exploration in the field of functional cure (clinical cure) for chronic hepatitis B (CHB).
Bepirovirsen (ASO)
Two oral presentations:
Title of Abstract: Rates of functional cure in participants with chronic hepatitis B virus (HBV) infection
treated with bepirovirsen: B-Well Phase 3 trials end of study results
Presenter:
Man-Fung Yuen, The University of Hong Kong
Time:
7 November 2026, 11:00 am – 11:15 am (local time)
Venue:
Convention Center: Bluebird Ballroom 1C
Topic:
Functional Cure and Novel Therapeutics in Chronic Hepatitis B
Title of Abstract: Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon
hepatitis B surface antigen at Week 12
Presenter:
Pietro Lampertico, University of Milan
Time:
7 November 2026, 11:15 am – 11:30 am (local time)
Venue:
Convention Center: Bluebird Ballroom 1C
Topic:
Functional Cure and Novel Therapeutics in Chronic Hepatitis B
2
A poster of distinction:
Title of Abstract: Up to 15 Months Durability of Functional Cure in Response to Bepirovirsen Therapy
in B-Well Responders Enrolled into B-Sure
Presenter:
Edward Gane, University of Auckland
About Bepirovirsen:
Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to inhibit the
replication of viral DNA in the body, suppress the level of hepatitis B surface antigen (HBsAg) in the
blood, and stimulate the immune system to increase the chances of a durable and sustained response.
Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to
address significant unmet need in hepatitis B, it was approved for marketing by Japan’s Ministry of
Health, Labor and Welfare (MHLW) in August 2026. It has also received Fast Track, Priority Review,
and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA), and has
been included in the Breakthrough Therapy Designation and priority review and approval procedures by
the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration.
By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman
Hong Kong, 14 October 2026
As at the date of this announcement, the Board of the Company comprises five executive Directors,
namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and
Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong,
Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.
3
no responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)
VOLUNTARY ANNOUNCEMENT
LATEST RESEARCH RESULTS ON TQ-A3334 “TLR7 AGONIST” AND
BEPIROVIRSEN “ASO”
TO BE PRESENTED AT 2026 AASLD
The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together
with its subsidiaries, the “Group”) announces that the results from a clinical study of TQ-A3334 (a
TLR7 agonist), a national Category 1 innovative drug independently developed by Chia Tai Tianqing
Pharmaceutical Group Co., Ltd. (“CTTQ”), a subsidiary of the Group, have been selected as a “LateBreaking Abstract” (LBA) at The Liver Meeting 2026 of the American Association for the Study of
Liver Diseases (AASLD) and will be presented in the form of an oral presentation. Bepirovirsen (ASO),
a product resulting from the strategic collaboration between CTTQ and GlaxoSmithKline (GSK), has
been selected for 2 oral presentations and 8 poster presentations (including one poster of distinction).
TQ-A3334 (TLR7 agonist)
An LBA:
Title of Abstract: Efficacy and Safety of an Oral TLR7 Agonist Through 48 Weeks in NAs-Treated
Chronic HBV Infection: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Presenter:
Professor Hong Tang, West China Hospital of Sichuan University
Date and Time:
8 November 2026, 5:30 pm – 5:45 pm (local time)
Venue:
Late Breaking Abstract Parallel Session 2
1
About TQ-A3334:
TQ-A3334 is an oral, selective Toll-like receptor 7 (TLR7) agonist that reshapes the body’s immune
response against HBV by activating innate and adaptive immune pathways and inducing interferon and
cytokine responses. It complements the direct antiviral effects of nucleos(t)ide analogues and represents
a significant exploration in the field of functional cure (clinical cure) for chronic hepatitis B (CHB).
Bepirovirsen (ASO)
Two oral presentations:
Title of Abstract: Rates of functional cure in participants with chronic hepatitis B virus (HBV) infection
treated with bepirovirsen: B-Well Phase 3 trials end of study results
Presenter:
Man-Fung Yuen, The University of Hong Kong
Time:
7 November 2026, 11:00 am – 11:15 am (local time)
Venue:
Convention Center: Bluebird Ballroom 1C
Topic:
Functional Cure and Novel Therapeutics in Chronic Hepatitis B
Title of Abstract: Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon
hepatitis B surface antigen at Week 12
Presenter:
Pietro Lampertico, University of Milan
Time:
7 November 2026, 11:15 am – 11:30 am (local time)
Venue:
Convention Center: Bluebird Ballroom 1C
Topic:
Functional Cure and Novel Therapeutics in Chronic Hepatitis B
2
A poster of distinction:
Title of Abstract: Up to 15 Months Durability of Functional Cure in Response to Bepirovirsen Therapy
in B-Well Responders Enrolled into B-Sure
Presenter:
Edward Gane, University of Auckland
About Bepirovirsen:
Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to inhibit the
replication of viral DNA in the body, suppress the level of hepatitis B surface antigen (HBsAg) in the
blood, and stimulate the immune system to increase the chances of a durable and sustained response.
Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to
address significant unmet need in hepatitis B, it was approved for marketing by Japan’s Ministry of
Health, Labor and Welfare (MHLW) in August 2026. It has also received Fast Track, Priority Review,
and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA), and has
been included in the Breakthrough Therapy Designation and priority review and approval procedures by
the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration.
By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman
Hong Kong, 14 October 2026
As at the date of this announcement, the Board of the Company comprises five executive Directors,
namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and
Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong,
Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.
3
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6b91b1956f· 2026-10-15 02:13 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前